Literature DB >> 9234177

Stem cell mobilization in normal donors.

A Tabilio1, F Falzetti, C Giannoni, F Aversa, M P Martelli, M Rossetti, P Caputo, F Chionne, C Gambelunghe, M F Martelli.   

Abstract

We studied peripheral blood and apheresis samples from 39 consecutive normal donors who were parents or siblings of patients who received matched or mismatched bone marrow transplants using a combination of rhG-CSF-mobilized peripheral blood stem cells (PBSCs) and bone marrow (BM). BM was harvested from donors 1-7 days before starting rhG-CSF treatment: 12 micrograms/kg/day rhG-CSF was administered by continuous s.c. infusion for 4-7 days. Peripheral blood progenitor cells were harvested by leukapheresis using an automated continuous-flow blood cell separator, beginning on day 4 of rhG/CSF, for 1-4 consecutive days. Peak peripheral blood CD34+ cell and CFU-GM levels were reached simultaneously on day 5 or 6 of rhG-CSF administration. Median peak levels were 1.65% for CD34+ cells (range 0.34%-4.7%) and 142 CFU-GM/10(5) plated cells (range 16-700). The greatest numbers of CD34+ cells and CFU-GM, expressed per liter of blood volume processed, were harvested during the second and third leukapheresis: CD34+ cells 37.77 +/- 25.48 x 10(6) and CFU-GM 3.32 +/- 2.51 x 10(6) during the second leukapheresis, and CD34+ cells 37.01 +/- 16.33 x 10(6) and CFU-GM 3.82 +/- 4.36 x 10(6) during the third. The number of CD34+ cells and CFU-GM did not correlate with the sex, age, or body weight of the donors. This study indicates that this protocol for administration of rhG-CSF mobilizes large numbers of hematopoietic progenitor cells into the peripheral blood and that bone marrow harvesting before G-CSF administration does not impair stem cell mobilization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234177     DOI: 10.1089/scd.1.1997.6.227

Source DB:  PubMed          Journal:  J Hematother        ISSN: 1061-6128


  4 in total

1.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

Authors:  Katia Perruccio; Antonella Tosti; Emanuela Burchielli; Fabiana Topini; Loredana Ruggeri; Alessandra Carotti; Marusca Capanni; Elena Urbani; Antonella Mancusi; Franco Aversa; Massimo F Martelli; Luigina Romani; Andrea Velardi
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

Review 2.  Stem cell bioprocessing: fundamentals and principles.

Authors:  Mark R Placzek; I-Ming Chung; Hugo M Macedo; Siti Ismail; Teresa Mortera Blanco; Mayasari Lim; Jae Min Cha; Iliana Fauzi; Yunyi Kang; David C L Yeo; Chi Yip Joan Ma; Julia M Polak; Nicki Panoskaltsis; Athanasios Mantalaris
Journal:  J R Soc Interface       Date:  2009-03-06       Impact factor: 4.118

3.  Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.

Authors:  Ivetta Danylesko; Rina Sareli; Nira Varda-Bloom; Ronit Yerushalmi; Noga Shem-Tov; Hila Magen; Avichai Shimoni; Arnon Nagler
Journal:  Int J Hematol       Date:  2021-07-02       Impact factor: 2.490

4.  Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.

Authors:  Nosha Farhadfar; Jack W Hsu; Brent R Logan; Jennifer A Sees; Pintip Chitphakdithai; Michele W Sugrue; Hisham Abdel-Azim; Paolo N Anderlini; Christopher Bredeson; Saurabh Chhabra; Miguel Angel Diaz; Siddhartha Ganguly; Peiman Hematti; Rammurti T Kamble; Kimberly A Kasow; Hillard M Lazarus; Debra Kelly Lynch; Hemant S Murthy; Richard F Olsson; Mona Papari; Donna Przepiorka; Bipin N Savani; Raquel Schears; Sachiko Seo; Melhem M Solh; Thomas Spitzer; Jean A Yared; Michael A Pulsipher; Nirali N Shah; Galen E Switzer; Dennis L Confer; Bronwen E Shaw; John R Wingard
Journal:  Blood Adv       Date:  2020-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.